Zydus Lifesciences has launched Anyra, a biosimilar to Regeneron Prescription drugs’ Aflibercept 2 mg indicated for sure eye ailments.
Zydus stated on Thursday that Anila is India’s first indigenously developed aflibercept 2mg biosimilar, and likewise introduced that it has signed agreements with Regeneron Prescription drugs and Bayer.
Anyra is indicated for the therapy of neovascular (moist) age-related macular degeneration, visible impairment as a result of macular edema secondary to retinal vein occlusion, visible impairment as a result of diabetic macular edema (DME), and several other different circumstances. Taken collectively, these signs signify numerous sufferers who require well timed anti-VEGF remedy to forestall irreversible imaginative and prescient loss. The corporate stated affordability and continuity of therapy are issues, as power retinal ailments require repeated intravitreal injections over an extended time frame.
“Anyra is a step within the transformation of reasonably priced retinal care in India. By providing high-quality aflibercept 2mg developed in India, we’re increasing affected person entry to this vital superior biologic remedy,” stated Sharbir P. Patel, Managing Director, Zydus Lifesciences.
